EP0623023A1 - Retroreverse pyrrole-amidino oligopeptide anticancer agent analogues, preparation of same, and pharmaceutical compositions containing such analogues - Google Patents

Retroreverse pyrrole-amidino oligopeptide anticancer agent analogues, preparation of same, and pharmaceutical compositions containing such analogues

Info

Publication number
EP0623023A1
EP0623023A1 EP93902141A EP93902141A EP0623023A1 EP 0623023 A1 EP0623023 A1 EP 0623023A1 EP 93902141 A EP93902141 A EP 93902141A EP 93902141 A EP93902141 A EP 93902141A EP 0623023 A1 EP0623023 A1 EP 0623023A1
Authority
EP
European Patent Office
Prior art keywords
pyrrole
methyl
carboxyamido
compound
per formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93902141A
Other languages
German (de)
French (fr)
Inventor
Federico Arcamone
Paolo Lombardi
Fabio Animati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Menarini Industrie Farmaceutiche Riunite SRL
Bristol Myers Squibb SpA
Original Assignee
Menarini Industrie Farmaceutiche Riunite SRL
Bristol Myers Squibb SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Menarini Industrie Farmaceutiche Riunite SRL, Bristol Myers Squibb SpA filed Critical Menarini Industrie Farmaceutiche Riunite SRL
Publication of EP0623023A1 publication Critical patent/EP0623023A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Definitions

  • Retroreverse pyrrole-amidino oligopeptide anticancer agent analogues preparation of same , and pharmaceutical compositions containing such analogues .
  • the present invention relates to anticancer agents as per general formula ( I )
  • n 0 or a whole number from 1 to 6
  • A a single chemical bond or an alicyclic or aromatic or heterocyclic residue
  • X 1 a chemical bond, the -NHCO- group or the -CONH- group
  • X 2 , X 3 the -CONH- or -NHCO- group and where:
  • R 1 and R 2 (equal) an oxiranomethyl or 1-aziridinomethyl or C 2 -
  • R 4 is C 1 -C 4 alkyl or phenyl
  • R 1 H
  • the invention further refers to the process for the preparation of the aforesaid products, the pharmaceutically acceptable salts thereof, and the pharmacetical compositions containing said products.
  • Dystamicin is an antibiotic already known having formula (A)
  • a requisite for the therapeutic progress in this field is, therefore, the discovery of compounds having molecular characteristics increasing their selectivity in inhibiting the proliferation of viruses and tumoural cells in respect of the healthy ones.
  • An object of this invention is the obtainment of anticancer and antiviral compounds and in particular of dystamicin analogues in which one or more carboxyamidic bonds has/have been replaced by a retrocarboxyamidic bond, containing new chemical modifications at the N-terminal side chain.
  • the said compounds have shown a high anticancer and antiviral activity and a high selectivity in inhibiting tumoural cells and viruses in respect of healthy cells.
  • the compounds as per the present invention are compounds as per general formula (I) and pharmaceutically acceptable salts thereof:
  • n 0 or a whole number from 1 to 6
  • A a single chemical bond or an alicyclic or aromatic or heterocyclic residue
  • X 1 a single chemical bond, the -NHCO- group or the -CONH- group
  • X 2 , X 3 the -CONH- or -NHCO- group and where:
  • R 1 and R 2 (equal) an oxiranomethyl or 1-aziridinomethyl or C 2 -
  • R 4 is C 1 -C 4 alkyl or phenyl
  • R 1 H
  • R 2 -CO-(CH 2 ) m -R 3 , where m is 0 or a whole number from
  • R 3 halogen, oxiranyl or methyloxiranyl or azirinidyl, cyclopropyl or a C 2 -C 6 alkenyl group substituted, if required, by halogens or a ketone or an ⁇ ,(S unsaturated alicylic lactone.
  • the invention also refers to pharmaceutical compositions containing the aforesaid compounds or the pharmaceutically acceptable salts therof, based on inorganic acids, e.g. hydrochloric or hydrobromic or sulphuric or nitric acids, etc., or on organic acids, e.g. acetic or propionic or succinic or malonic or citric or tartaric or methanesulfonic or p-toluenesulfonic acids, etc.
  • inorganic acids e.g. hydrochloric or hydrobromic or sulphuric or nitric acids, etc.
  • organic acids e.g. acetic or propionic or succinic or malonic or citric or tartaric or methanesulfonic or p-toluenesulfonic acids, etc.
  • n is as defined above
  • A is a single cyclohexyl or p-phenyl or 1-methylpyrrole or thiophene or thiazole or imidazole or furan or isoxazole or oxazole or triazole or pyridine or pyrrole chemical bond
  • X 1 , X 2 , X 3 are as defined above.
  • the compounds as per general formula (I) may be prepared on the basis of the following processes:
  • n, A. R 1 , R 2 and X 1 are as defined above, or a reactive derivative thereof, with compound as per formula (III)
  • n, A, R 1 , R 2 and X 1 are as defined above, or a reactive precursor of same, with compound as per formula (V)
  • reaction of compound as per formula (II) with compound as per formula (III) was conducted in the presence of condensers, such as DCC (dicyclohexyl carbodiimide) or EDC [1-(3-dimethylaminopro ⁇ yl)-3- ethylcarbodiimide hydrochloride] either in the presence or in the absence of hydroxybenzotriazole or BOP (benzotriazol)-1- yloxytris (dimethylaminophosphonium hexafluorophosphate) or a reactive derivative of (II), such as acylchloride, acylimidazole, acylazide corresponding to acid (II) or an active ester, such as 2,4,5 trichlorophenoxyester or N-oxysuccinimidoester of acid (II) or its anhydride.
  • condensers such as DCC (dicyclohexyl carbodiimide) or EDC [1-(3-
  • reaction of ( II) with (III) is preferably carried out at molar ratios from 1 : 1 to 1 : 3 in an inert organic solvent , such as dimethylsulphoxide , hexamethylphosphorotriamide , dimethylacetamide or preferably dimethylformamide, in the presence of a condenser of the type mentioned above and of N-hydroxybenzotriazole or BOP and in the presence of an organic base , such as triethylamine, diisopropylethylamine and 1 ,8-bis- (dimethylamino) -naphthalene.
  • an inert organic solvent such as dimethylsulphoxide , hexamethylphosphorotriamide , dimethylacetamide or preferably dimethylformamide
  • an organic base such as triethylamine, diisopropylethylamine and 1 ,8-bis- (dimethylamino) -naphthalene.
  • the reaction temperature may range from -10 ° C to 50 °C and the reaction time from 2 to 48 hrs .
  • reaction of compound as per formula (II) with compound as per formula (III) may also be conducted with a reactive derivative of compound as per formula (II) of the type mentioned above in a water- organic solvent biphasic system as for the amidation according to Schotten-Baumann, or in an organic solvent such as benzene, toluene, halogenated hydrocarbons , ethanol , methanol , tetrahydrofuran, dioxane , dimethylformamide , or in aqueous dioxane , ethanol , methanol.
  • a water- organic solvent biphasic system as for the amidation according to Schotten-Baumann
  • organic solvent such as benzene, toluene, halogenated hydrocarbons , ethanol , methanol , tetrahydrofuran, dioxane , dimethylformamide , or in aqueous dioxane , ethanol , methanol.
  • reaction may be carried out also in the presence of an inorganic base, such as a hydroxide, a carbonate or a bicarbonate of an alkali metal , preferably sodium , potassium or barium or an organic base, such as triethylamine, diisopropylethylamine, pyridine or N,N-dimethylaminopyridine.
  • an inorganic base such as a hydroxide, a carbonate or a bicarbonate of an alkali metal , preferably sodium , potassium or barium or an organic base, such as triethylamine, diisopropylethylamine, pyridine or N,N-dimethylaminopyridine.
  • an organic base such as triethylamine, diisopropylethylamine, pyridine or N,N-dimethylaminopyridine.
  • a reactive precursor of compound as per formula (IV) may be e. g. compound having formula (VI)
  • the reaction of an isocyanate as per formula (IV) with an amidino acid as per formula (V) is preferably conducted with an acylazide as per formula (VI) as a reactive precursor of an isocyanate as per formula (IV).
  • the reaction may be carried out in an aromatic hydrocarbon as solvent, such as for example benzene or toluene at 50°C-100°C for 5-20 hrs.
  • a molar quantity of an organic base e.g. triethylamine. pyridine, and the like, may be utilized in the reaction to salify an acid as per formula (V).
  • the process of formation of an isocyanate from a reactive precursor, e.g. an acylazide is well known in organic chemistry (cf. Curtius's reaction).
  • An azide as per formula (VI) may be prepared by causing to react compound as per formula (II) with diphenylphosphorazide or sodium azide (NaN 3 ).
  • R 5 is a typical protective group of carboxylic acids, such as methyl, ethyl, t-butyl, benzyl, 2-trimethylxylylethyl, 2,2,2- trichloroethyl.
  • the hydrolysis of compound as per formula (VII) may be performed according to the methods and procedures known in organic chemisty, as, for instance, referred to in T.W. Greene, Protective Groups in Organic Synthesis, J. Wiley and Sons, Interscience Publishers, 1981.
  • compound as per formula (II), where X 1 , n and A are as defined above and R 1 and R 2 are equal and stand for a C 2 -C 4 alkyl group substituted in position 2 by a halogen or an -OSO 2 R 4 group, where R 4 is as defined above may be prepared, if preferred so, by causing compound as per formula (II), where X 1 , n and A are as defined above and R 1 and R 2 are equal and stand for a C 2 -C 4 alkyl group substituted in position 2 by a hydroxy group, to react with a halogenating agent, e.g.
  • a halogenating agent e.g.
  • R 5 is as defined above.
  • An acid reactive derivative as per formula (VIII) may be the same as that reported hereinabove for compound as per formula (II) and the reaction may be carried out under conditions analogous to those reported for the amidation of compound as per formula (II) with compound as per formula (III).
  • R 1 , R 2 and R 5 are as defined above, are either known [cf. e.g. J. Med. Chem., 32, 774 (1989)] or prepared on the basis of standard procedures starting from known compounds.
  • n, A, and R 5 are as defined above.
  • compound as per formula (IV) may be prepared from a corresponding reactive precursor as per formula (VI) on the basis of Curtius's reaction.
  • An acylazide as per formula (VI) may be prepared from the corresponding acid as per formula (II) on the basis of the methods described in Tetr., 30, 2151 (1974).
  • R 6 is a protective group for a carboxylic acid, such as for example 2,2,2 trichloroethyl, benzyl, phenacyl, and the like, and X 3 is as already defined.
  • the R 6 group may be removed e.g. with Zn in acetic acid or by catalytic hydrogenation on Pd/C in H 2 O, MeOH, EtOH, formic acid and their mixtures.
  • a reactive derivative of compound (XV) may be of the same type as those reported for compounds as per formula (II) and the amidation reaction between (XV) and (XVI) may be carried out as reported above for the reaction between compounds as per formulas (II) and (III).
  • Compounds as per formulas (XV) and (XVI) may be prepared as disclosed in the applicant's Italian Patent N. 22154 dated 22nd Nov. 1990 and referred to here for reference.
  • a reactive precursor of compound ( XVII ) may be a compound as per formula (XIX)
  • R 6 is as defined above .
  • reaction of an isocyanate as per formula (XVII) with an acid as per formula (XVIII) may preferably be conducted using an azide as per formula (XIX) as reactive precursor of (XVII) under conditions analogous to those reported above for the reaction of compound as per formula (VI) with compound as per formula (V) .
  • the present invention further refers to pharmaceutical compositions containing as active ingredient a compound as per formula (I) or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable vector or diluent.
  • a therapeutically effective amount of compound as per formula (I) according to the invention is combined with an inert and pharmaceutically acceptable vector.
  • the vectors used may be the traditional ones and the compositions may be formulated according to the usual methods .
  • the compounds as per the present invention are useful for the therapeutic treatment of humans and animals .
  • the compounds as per the Invention are useful as antitumoural and/or antiviral agents when administered in therapeutically effective amounts , e.g. an adequate dosage for adult administration may range from 0.1 to 100 mg approx. pro dose from 1 to 4 times /day.
  • X 3 -CONH-) (190 mg; 0.469 mM), 63 mg of N- hydroxybenzotriazole (H0BT) (0.469 mM), 103 mg of 1,8-bis- (dimethylamino)-naphthalene (0.480 mM) and by subsequent additions [1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) (162 mg; 0.848 mM) .
  • H0BT N- hydroxybenzotriazole
  • EDC 1,8-bis- (dimethylamino)-naphthalene

Abstract

Composés répondant à la formule générale (I), et leurs sels pharmaceutiquement acceptables, pouvant être utilisés comme agents anticancéreux et antiviraux.Compounds corresponding to the general formula (I), and their pharmaceutically acceptable salts, which can be used as anticancer and antiviral agents.

Description

Retroreverse pyrrole-amidino oligopeptide anticancer agent analogues , preparation of same , and pharmaceutical compositions containing such analogues .
Field of the Invention
The present invention relates to anticancer agents as per general formula ( I )
(I)
and pharmaceutically acceptable salts thereof ,
where:
n = 0 or a whole number from 1 to 6
A = a single chemical bond or an alicyclic or aromatic or heterocyclic residue,
X1 = a chemical bond, the -NHCO- group or the -CONH- group
X2, X3 (either equal or different) = the -CONH- or -NHCO- group and where:
i) R1 and R2 (equal) = an oxiranomethyl or 1-aziridinomethyl or C2-
C4 alkyl group, substituted in position 2, if required, by a hydroxy or C2-C4 alcoxy halogen or -OSO2R4 group, where:
R4 is C1-C4 alkyl or phenyl
or ii) R1 = H, R2 as defined above
or
iii) R1 = H, R2 = -CO-(CH2)m-R3, where m is 0 or a whole number from 1 to 4 and R3 = halogen, oxiranyl or methyloxiranyl or azirinidyl, cyclopropyl or a C2-C6 alkenyl group substituted, if required, by halogens or a ketone or an α.β unsaturated alicylic lactone.
Considering that:
if R1 and R2 are as defined under i) and ii) and X1 is a single chemical bond, A is a single chemical bond and n = 0;
if R1 and R2 are as defined under iii). X1 and A are single chemical bonds and n = 0;
if X1 is a single chemical bond or the -CONH- group and n = 0, X2 = X3 = -CONH- is impossible.
The invention further refers to the process for the preparation of the aforesaid products, the pharmaceutically acceptable salts thereof, and the pharmacetical compositions containing said products.
State of the art
Dystamicin is an antibiotic already known having formula (A)
belonging to the pyrrole-amidino antibiotic group, endowed with interesting antiviral properties, e.g. against herpesviruses and Moloney sarcoma virus, and capable of interacting reversibly and selectively with dA and dT base-rich DNA sequences, thus interfering both in replication and transcription processes (cf. F. Arcamone, Molecular basis of specificity in nucleic acid-drug interaction, B. Pullman and J. Jorterez, eds., 369-383 (1990), Kluwer Academic Publishers).
As known, the severe side effects that, at present, are caused by the intake of antiviral and anticancer agents limit their use in a large number of cases, which, instead, should benefit from the therapy. Moreover, the clinical treatment of serious solid tumours, e.g. of lungs and ovaries, must be developed, as none - for the time being - is adequate.
A requisite for the therapeutic progress in this field is, therefore, the discovery of compounds having molecular characteristics increasing their selectivity in inhibiting the proliferation of viruses and tumoural cells in respect of the healthy ones.
Detailed description of the invention
An object of this invention is the obtainment of anticancer and antiviral compounds and in particular of dystamicin analogues in which one or more carboxyamidic bonds has/have been replaced by a retrocarboxyamidic bond, containing new chemical modifications at the N-terminal side chain. The said compounds have shown a high anticancer and antiviral activity and a high selectivity in inhibiting tumoural cells and viruses in respect of healthy cells. The compounds as per the present invention are compounds as per general formula (I) and pharmaceutically acceptable salts thereof:
where:
n = 0 or a whole number from 1 to 6
A = a single chemical bond or an alicyclic or aromatic or heterocyclic residue,
X1 = a single chemical bond, the -NHCO- group or the -CONH- group
X2, X3 (either equal or different) = the -CONH- or -NHCO- group and where:
i) R1 and R2 (equal) = an oxiranomethyl or 1-aziridinomethyl or C2-
C4 alkyl group, substituted in position 2, if required, by a hydroxy or C2-C4 alcoxy halogen or an -OSO2R4 group, where:
R4 is C1-C4 alkyl or phenyl
or
ii) R1 = H, R2 as defined above
or
iii) R1 = H, R2 = -CO-(CH2)m-R3, where m is 0 or a whole number from
1 to 4 and R3 = halogen, oxiranyl or methyloxiranyl or azirinidyl, cyclopropyl or a C2-C6 alkenyl group substituted, if required, by halogens or a ketone or an α,(S unsaturated alicylic lactone.
Considering that:
if R1 and R2 are as defined under i) and ii) and X1 is a single chemical bond, A is a single chemical bond and n = 0;
if R1 and R2 are as defined under iii), X1 and A are single chemical bonds and n = 0;
if X1 is a single chemical bond or the -CONH- group and n = 0, X2 = X3 = -CONH- is impossible.
The invention also refers to pharmaceutical compositions containing the aforesaid compounds or the pharmaceutically acceptable salts therof, based on inorganic acids, e.g. hydrochloric or hydrobromic or sulphuric or nitric acids, etc., or on organic acids, e.g. acetic or propionic or succinic or malonic or citric or tartaric or methanesulfonic or p-toluenesulfonic acids, etc.
According to the present invention, the compounds as per formula (I) are preferred, where:
n is as defined above
A is a single cyclohexyl or p-phenyl or 1-methylpyrrole or thiophene or thiazole or imidazole or furan or isoxazole or oxazole or triazole or pyridine or pyrrole chemical bond
R^ and R2 (when R2 is not -CO-(CH2)m-R3 ) preferably stand for an ethyl or 2-chloroethyl or methanesulfonylethyl and when R2 = -CO- (CH2)m-R3, R3 preferably stands for chlorine or bromine, or a 3- methyloxyranyl or ethenyl or 1-chloroethenyl or 1-bromoethenyl group where:
m = 0, 1. 2.
X1, X2, X3 are as defined above.
Particularly preferred are the following compounds:
3-[l-Methyl-4-[1-methyl-4-[1-methyl-4-[4-[N,N-bis(2-chloroethyl)- amino]benzenecarboxyamido]pyrrole-2-carboxyamido]pyrrole-2- aminocarbonyl]pyrrole-2-carboxyamido]propionamidino hydrochloride;
3-[l-Methyl-4-[1-methyl-4-[1-methyl-4-[4-[N,N-bis(2-chloroethyl)- amino]benzeneaminocarbonyl]pyrrole-2-carboxyamido]pyrrole-2- carboxyamido]pyrrole-2-carboxyamido]propionamidino hydrochloride;
3-[1-Methyl-4-[1-methyl-4-[1-methyl-4-[4-[N,N-bis(2-chloroethyl)- amino]benzeneaminocarbonyl]pyrrole-2-carboxyamido]pyrrole-2- aminocarbonyl]pyrrole-2-carboxyamido]propionamidino hydrochloride;
3-[1-Methyl-4-[1-methyl-4-[1-methyl-4-[4-[N,N-bis(2-chloroethyl)- amino]benzenecarboxyamido]pyrrole-2-aminocarbonyl]pyrrole-2- carboxyamido]pyrrole-2-carboxyamido]propionamidino hydrochloride;
3-[1-Methyl-4-[1-methyl-4-[1-methyl-4-[4-[N,N-bis(2-chloroethyl)- amino]thiophene-2-carboxyamido]pyrrole-2-carboxyamido]pyrrole-2- aminocarbonyl]pyrrole-2-carboxyamido]propionamidino hydrochloride; 3-[1-Methyl-4-[1-methyl-4-[1-methyl-4-[1-methyl-4-[N,N-bis(2- chloroethyl)-amino]pyrrole-2-carboxyamido]pyrrole-2- carboxyamido]pyrrole-2-aminocarbonyl]pyrrole-2- carboxyamido]propionamidino hydrochloride;
3-[1-Methyl-4-[1-methyl-A-[1-methyl-4-[N,N-bis(2-chloroethyl)- amino]pyrrole-2-carboxyamido]pyrrole-2-aminocarbonyl ]pyrrole-2- carboxyamido]propionamidino hydrochloride ;
3- [ 1-Methyl-4- [ 1 -methyl-4- [ 1-methyl-4- [N , N-bis (2-chloroethyl ) - amino]pyrrole-2-aminocarbonyl]pyrrole-2-carboxyamido]pyrrole-2- carboxyamido]propionamidino hydrochloride;
3-[1-Methyl-4-[1-methyl-4-[1-methyl-4-[N,N-bis(2-chloroethyl)- amino]pyrrole-2-aminocarbonyl]pyrrole-2-aminocarbonyl]pyrrole-2- carboxyamido]propionamidino hydrochloride;
3-[1-Methyl-4-[1-methyl-4-[1-methyl-4-[6-[4-[N,N-bis(2-chloroethyl)- amino]phenyl]hexaneaminocarbonyl]pyrrole-2-carboxyamido]pyrrole-2- carboxyamido]pyrrole-2-carboxyamido]propionamidino hydrochloride;
3-[1-Methyl-4-[1-methyl-4-[1-methyl-4-(3-methyloxirano- carbonylamino)pyrrole-2-carboxyamido]pyrrole-2- aminocarbonyl]pyrrole-2-carboxyamido]propionamidino hydrochloride; 3-[1-Methyl-4-[1-methyl-4-[1-methyl-4-
(cyclopropylcarbonylamino)pyrrole-2-carboxyamido]pyrrole-2- aminocarbonyl]pyrrole-2-carboxyamido]propionamidino hydrochloride;
3-[1-Methyl-4-[1-methyl-4-[1-methyl-4-[1-aziridino)
carbonylamino]pyrrole-2-carboxyamido]pyrrole-2- aminocarbonyl]pyrrole-2-carboxyamido]propionamidino hydrochloride;
3-[1-Methyl-4-[1-methyl-4-[1-methyl-4-(α-chloroacrylamido)pyrrole-2- carboxyamido]pyrrole-2-aminocarbonyl]pyrrole-2- carboxyamido]propionamidino hydrochloride;
3-[1-Methyl-A-[1-methyl-4-[1-methyl-4-[2[4-[N,N-bis(2-chloroethyl)- amino]phenyl]ethanaminocarbonyl]pyrrole-2-carboxyamido]pyrrole-2- carboxyamido]pyrroie-2-carboxyamido] propionamidino hydrochloride;
3-[1-Methyl-4 -[ 1-methyl-4-[ 1-methyl-4-[4-[N ,N-bis (2-chloroethyl) - amino]benzylaminocarbonyl]pyrrole-2-carboxyamido]pyrrole-2- carboxyamido]pyrrole-2-carboxyamido]propionamidino hydrochloride; 3-[1-Methyl-4-[1-methyl-4-[1-methyl-4-[3-[4-[N,N-bis(2-chloroethyl)- amino]-phenyl]propanamino-carbonyl]pyrrole-2-carboxyamido]pyrrole-2- carboxyamido]propionamidino hydrochloride;
3-[1-Methyl-4-[1-methyl-4-[1-methyl-4-[4-[4-[N,N-bis(2-chloroethyl)- amino]-phenyl]butanamido]pyrrole-2-aminocarbonyl]pyrrole-2- carboxyamido]pyrrole-2-carboxyamido]propionamidino hydrochloride;
N-deformyl-N-[4-[4-[N,N-bis(2-chloroethyl)amino]phenyl]
butanoyl]dystamicin hydrochloride.
The compounds as per general formula (I) may be prepared on the basis of the following processes:
a) Reaction of compound as per formula (II)
where n, A. R1, R2 and X1 are as defined above, or a reactive derivative thereof, with compound as per formula (III)
where X3 is as defined above, to obtain compounds as per formula (I) where X2 = -CONH- and A, n, R1, R2, X1 and X3 are as defined above. b) Reaction of compound as per formula (IV)
where n, A, R1, R2 and X1 are as defined above, or a reactive precursor of same, with compound as per formula (V)
where X3 is as defined above, to obtain compounds as per formula (I), where X2 = -NHCO- and A, n, R1, R2, X1 and X3 are as defined above.
The reaction of compound as per formula (II) with compound as per formula (III) was conducted in the presence of condensers, such as DCC (dicyclohexyl carbodiimide) or EDC [1-(3-dimethylaminoproρyl)-3- ethylcarbodiimide hydrochloride] either in the presence or in the absence of hydroxybenzotriazole or BOP (benzotriazol)-1- yloxytris (dimethylaminophosphonium hexafluorophosphate) or a reactive derivative of (II), such as acylchloride, acylimidazole, acylazide corresponding to acid (II) or an active ester, such as 2,4,5 trichlorophenoxyester or N-oxysuccinimidoester of acid (II) or its anhydride.
The reaction of ( II) with (III) is preferably carried out at molar ratios from 1 : 1 to 1 : 3 in an inert organic solvent , such as dimethylsulphoxide , hexamethylphosphorotriamide , dimethylacetamide or preferably dimethylformamide, in the presence of a condenser of the type mentioned above and of N-hydroxybenzotriazole or BOP and in the presence of an organic base , such as triethylamine, diisopropylethylamine and 1 ,8-bis- (dimethylamino) -naphthalene.
The reaction temperature may range from -10 ° C to 50 °C and the reaction time from 2 to 48 hrs .
The reaction of compound as per formula (II) with compound as per formula (III) may also be conducted with a reactive derivative of compound as per formula (II) of the type mentioned above in a water- organic solvent biphasic system as for the amidation according to Schotten-Baumann, or in an organic solvent such as benzene, toluene, halogenated hydrocarbons , ethanol , methanol , tetrahydrofuran, dioxane , dimethylformamide , or in aqueous dioxane , ethanol , methanol. The reaction may be carried out also in the presence of an inorganic base, such as a hydroxide, a carbonate or a bicarbonate of an alkali metal , preferably sodium , potassium or barium or an organic base, such as triethylamine, diisopropylethylamine, pyridine or N,N-dimethylaminopyridine. The reaction is usually conducted at ambient temperature and the time required ranges from 2 to 2k hrs. In process (b) a reactive precursor of compound as per formula (IV) may be e. g. compound having formula (VI)
The reaction of an isocyanate as per formula (IV) with an amidino acid as per formula (V) is preferably conducted with an acylazide as per formula (VI) as a reactive precursor of an isocyanate as per formula (IV). The reaction may be carried out in an aromatic hydrocarbon as solvent, such as for example benzene or toluene at 50°C-100°C for 5-20 hrs. A molar quantity of an organic base, e.g. triethylamine. pyridine, and the like, may be utilized in the reaction to salify an acid as per formula (V). The process of formation of an isocyanate from a reactive precursor, e.g. an acylazide, is well known in organic chemistry (cf. Curtius's reaction).
An azide as per formula (VI) may be prepared by causing to react compound as per formula (II) with diphenylphosphorazide or sodium azide (NaN3).
In process (a) compound as per formula (II), where X1, n, A, R1 and R2 are as defined above, may be prepared by hydrolysis of compound as per formula (VII)
where R5 is a typical protective group of carboxylic acids, such as methyl, ethyl, t-butyl, benzyl, 2-trimethylxylylethyl, 2,2,2- trichloroethyl. The hydrolysis of compound as per formula (VII) may be performed according to the methods and procedures known in organic chemisty, as, for instance, referred to in T.W. Greene, Protective Groups in Organic Synthesis, J. Wiley and Sons, Interscience Publishers, 1981.
In particular, compound as per formula (II), where X1, n and A are as defined above and R1 and R2 are equal and stand for a C2-C4 alkyl group substituted in position 2 by a halogen or an -OSO2R4 group, where R4 is as defined above, may be prepared, if preferred so, by causing compound as per formula (II), where X1, n and A are as defined above and R1 and R2 are equal and stand for a C2-C4 alkyl group substituted in position 2 by a hydroxy group, to react with a halogenating agent, e.g. SOCl2 or POCl3 or CH3SO2Cl/pyridine, to form compounds as per formula (II), where R1 and R2 are equal and stand for a C2-C4 alkyl group substituted in position 2 by a halogen, e.g. chlorine; or with a sulphonic acid reactive derivative as per formula R4SO3H, such as the corresponding chloride or anhydride, to form compounds as per formula (II), where R1 and R2 are equal and stand for a C2-C4 alkyl group substituted in position 2 by an -OSO2R4 group.
A compound as per formula (VII), where X1 = -CONH-, R1, R2, R5, n and A are as defined above (excepting when R1 = H and R2 = -CO- (CH2)m-R3) may be prepared by causing compound as per formula (VIII)
where A, n, R1 and R2 are as defined above (excepting when R1 = H and R2 = -CO- (CH2)m-R3) or a reactive derivative of same, to react with compound as per formula (IX)
where R5 is as defined above.
An acid reactive derivative as per formula (VIII) may be the same as that reported hereinabove for compound as per formula (II) and the reaction may be carried out under conditions analogous to those reported for the amidation of compound as per formula (II) with compound as per formula (III).
Compounds as per formula (VIII) are either known or prepared on the basis of classical procedures of organic chemistry starting from known compounds, as shown e.g. in J. Med. Chem., 32, 774 (1989) or J. Org. Chem., 26, 4996 (196l) or J. Med. Chem., 33, 1177 (1990). Compounds as per formula (IX). where R5 is as defined above are either known [cf. e.g. J. Org. Chem., 46, 3492 (1981)] or may be prepared on the basis of standard procedures starting from known compounds as shown e.g. in Tetr., 34, 2389 (1998). Compounds as per formula (VII), where R1 and R2 are as defined under i) and ii) and X1 is a single chemical bond, A is a single chemical bond and n = 0, i.e. compounds as per formula (X)
where R1, R2 and R5 are as defined above, are either known [cf. e.g. J. Med. Chem., 32, 774 (1989)] or prepared on the basis of standard procedures starting from known compounds.
Compounds as per formula (VII), where R1 and R2 are as defined under iii) and X1 and A are both simple chemical bonds and n = 0, i.e. compounds as per formula (XI)
where m, R3, and R5 are as described above, may be prepared either on the basis of standard chemical procedures as e.g. described for the amidation reaction of compound as per formula (II) with compound as per formula (III) or as described in J. Med. Chem., 31, 341 (1988).
Compound as per formula (VII), where X1 = -NHCO-, n, A, R1 and R2 are as defined above (excepting when R1 = H and R2 = -CO-(CH2)m-R3) may be prepared by causing to react compound as per formula (XII) with compound as per formula ( XIII )
where n, A, and R5 are as defined above.
Amidation of compound (XII) with compound (XIII) may be performed under conditions analogous to those reported for the reaction between compound as per formula (II) with compound as per formula
(III).
Compounds as per formula (XII) are either known or may be prepared on the basis of methods described e.g. in J. Med. Chem., 33. 112
(1990).
Compound as per formula (XIII), where R5 is as defined above is either known or may be prepared on the basis of methods already known [(J. Org. Chem., 43, 4849 (1978); 51, 3125 (1986)].
Compound as per formula (III), where X3 is -CONH-, is either known or may be prepared as described e.g. in J. Org. Chem., 50, 3774 (1985); compound as per formula (II), where H3 is -NHCO- may be prepared as disclosed in the applicant's Italian Patent N. 22154 and referred to here for reference.
In process (ii), compound as per formula (IV) may be prepared from a corresponding reactive precursor as per formula (VI) on the basis of Curtius's reaction. An acylazide as per formula (VI) may be prepared from the corresponding acid as per formula (II) on the basis of the methods described in Tetr., 30, 2151 (1974).
Compound as per formula (V) may be obtained by reductive lysis of the ester group of compound as per formula (XIV)
where R6 is a protective group for a carboxylic acid, such as for example 2,2,2 trichloroethyl, benzyl, phenacyl, and the like, and X3 is as already defined.
The R6 group may be removed e.g. with Zn in acetic acid or by catalytic hydrogenation on Pd/C in H2O, MeOH, EtOH, formic acid and their mixtures.
Compound as per formula (XIV), where X3 = -CONH-, may be prepared by causing to react compound as per formula (XV)
where R6 is as defined above, or a reactive derivative of same, with compound as per formula (XVI)
A reactive derivative of compound (XV) may be of the same type as those reported for compounds as per formula (II) and the amidation reaction between (XV) and (XVI) may be carried out as reported above for the reaction between compounds as per formulas (II) and (III). Compounds as per formulas (XV) and (XVI) may be prepared as disclosed in the applicant's Italian Patent N. 22154 dated 22nd Nov. 1990 and referred to here for reference.
Compounds as per formula (XIV), where X3 = -NHCO- may be prepared by causing to react compound as per formula (XVII)
where R6 as defined above, or an active precursor of same, with compound as per formula (XVIII)
A reactive precursor of compound ( XVII ) may be a compound as per formula (XIX)
where R6 is as defined above .
The reaction of an isocyanate as per formula (XVII) with an acid as per formula (XVIII) may preferably be conducted using an azide as per formula (XIX) as reactive precursor of (XVII) under conditions analogous to those reported above for the reaction of compound as per formula (VI) with compound as per formula (V) .
Compounds as per formulas (XVIII ) and (XIX) may be prepared as disclosed in the applicant ' s Italian Patent N . 22154 dated 22nd Nov. 1990 and referred to here for reference.
The present invention further refers to pharmaceutical compositions containing as active ingredient a compound as per formula (I) or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable vector or diluent.
A therapeutically effective amount of compound as per formula (I) according to the invention is combined with an inert and pharmaceutically acceptable vector. The vectors used may be the traditional ones and the compositions may be formulated according to the usual methods . The compounds as per the present invention are useful for the therapeutic treatment of humans and animals . In particular , the compounds as per the Invention are useful as antitumoural and/or antiviral agents when administered in therapeutically effective amounts , e.g. an adequate dosage for adult administration may range from 0.1 to 100 mg approx. pro dose from 1 to 4 times /day.
The following examples further illustrate the claimed invention. These examples are illustrative only; in no event are they to be regarded as limiting the scope of the invention.
EXAMPLE 1
1-Methyl-4-[4-[N,N bis(2-hydroxyethyl)-amino]benzeneaminocarbo- nyl]pyrrole-2-carboxylic acid methyl ester (VII, X1 = -NHCO-, A = p- phenylene, n = 0, R1 = R2 = 2-hydroxyethyl, R5 = CH3 )
A solution of N,N bis(2-hydroxyethyl)1,4-phenylendiamine (XII, A = p-phenylene, n = 0, R1 = R2 = 2-hydroxyethyl) (0.87 g; 4.42 mM), prepared as described in J. Med. Chem., 33, 112 (1990) in MeOH (40 ml) was added with a benzene solution (30 ml) of 1-methyl-2- carbomethoxy-4-pyrrolecarboxylic acid (XIII, R5 = methyl) (1.8 g;
8.85 mM) obtained from (XIII) (1.6 g; 8.85 mM) by reflux with SOCl2
(4.5 ml; 62 mM) in benzene (120 ml).
After a 1-hr stirring at ambient temperature, the reaction mixture was evaporated to dryness and the residue was separated by chromatography on silica gel (eluent CH2Cl2/MeOH 9/1 ) to form 1.35 g of product (VII, X1 = -NHCO-, A = phenylene, n = 0, R 1 = R2 = 2- hydroxyethyl, R5 = methyl) (yield 84%).
1H-NMR MeOH-d4δ: 3.70 (t, 4H); 3-87 (t. 4H); 3-99 (s, 3H); 4.13 (s, 3H); 6.90 (d. 2H); 7-56 (d, 2H) ; 7.6l (d, 1H) ; 7-73 (d. 1H).
EXAMPLE 2
1-Methyl-4-[4-[N , N-bis ( 2-hydroxyethyl ) -amino]benzeneamino- carbonyl ]pyrrole-2-carboxyli c acid ( II , X1 = -NHCO- , A = p-phenylene , n = 0 , R1 = R2 = 2-hydroxyethyl )
A solution of VII ( X1 = -NHCO- , A = p-phenylene , n = 0 , R1 = R2 = 2-hydroxyethyl, R5 = methyl) 0.53 g: 1-46 mM) in MeOH (3 ml) and 10% NaOH aqueous solution (2.5 ml) was refluxed for 3 hrs, concentrated to small volume, acidified with HCl 1 N to a pH equal to 6, and evaporated to dryness. The residue was taken up with cold MeOH, centrifuged, and evaporated to dryness to form 460 mg of II (X1 = - NHCO-, A = p-phenylene, n = 0, R1 = R2 = 2-hydroxyethyl) (yield
91%).
1H-NMR DMSO-d6 δ: 3-36 (t. 4H) ; 3-52 (t, 4H) ; 3-89 (s. 3H) ; 6.61 (d,
2H); 7.12 (d, 1H); 7-37 (d. 1H) ; 7-49 (d. 2H) ; 9-27 (s, 1H) .
EXAMPLE 3
1-Methyl-4-[4-[N,N-bis(2-chloroethyl)-amino]benzeneamino- carbonyl]pyrrole-2-carboxylic acid (II, X1 = -NHCO-, A = p-phenylene, n = 0, R1 = R2 = 2-chloroethyl)
A solution of II (X1 = -NHCO-, A = p-phenylene, n = 0, R1 - R2 = 2-hydroxyethyl) (0.38 g; 1.09 mM) in anhydrous pyridine (15 ml) cooled to 0°C-5°C was added with methanesulphonyl chloride (0.5 ml;
6.46 mM).
After a 1-hr stirring at ambient temperature and lr hr at 75°C, the reaction mixture was evaporated to dryness and the residue was chromatographed on silica gel (eluent CHClo 85/MeOH 15) to form 167 mg of II (X1 = -NHCO-, A = p-phenylene, n = 0, R1 = R2 = 2- chloroethyl) (yield 40%).
1H-NMR DMSO-d6 δ: 3.6-3-75 (m. 8H) ; 3-85 (s, 3H) ; 6.69 (d, 2H) ;
7.34 (d, 1H); 7-53 (d, 2H); 7-56 (d, 1H) .
EXAMPPE 4 3-[1-Methyl-4-[1-methyl-4-[1-methyl-4-[4-[N,N-bis(2-chloroethyl)- amino]benzeneaminocarbonyl]pyrrole-2-carboxyamido]pyrrole-2- carboxyamido]pyrrole-2-carboxyamido]propionamidino hydrochloride (I, X1 = -NHCO-, X2 = X3 = -CONH-, n = 0, A = p-phenylene, R1 = R2 = 2-chloroethyl)
A solution of II (X1 = -NHCO-, A = p-phenylene, n = 0, R1 = R2 = 2-chloroethyl) (0.172 g; 0.447 mM) in anhydrous dimethylformamide (10 ml) was added in the order with 190 mg of 1-methyl-4-(1-methyl- 4-aminopyrrole-2-carboxyamido)-pyrrole-2-carboxyamidoproprionamidino hydrochloride (III. X3 = -CONH-) (190 mg; 0.469 mM), 63 mg of N- hydroxybenzotriazole (H0BT) (0.469 mM), 103 mg of 1,8-bis- (dimethylamino)-naphthalene (0.480 mM) and by subsequent additions [1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) (162 mg; 0.848 mM) . After a 1-hr stirring at ambient temperature the reaction mixture was evaporated to dryness and the residue was chromatographed on silica gel (eluent CHCWEtOH 98% 6/4) to form 139 mg of I (X1 = -NHCO-, X2 = X3 = -CONH-, n = 0, A = p-phenylene, R1 = R2 = 2-chloroethyl) (yield 42%).
1H-NMR DMSO-d6 δ: 2.63 (t, 2H); 3-50 (q, 2H); 3.81 (s, 3H); 3-86 (s, 3H); 3-92 (s, 3H); 6.23 (d, 2H); 6.95 (d, 1H); 7-05 (d, 1H); 7.18 (d, 1H); 7.24 (d, 1H); 7.41 (d, 1H); 7-53 (d. 2H); 7.69 (d. 1H); 8.19 (t. 1H); 9-50 (s, 1H); 9-53 (bs. 2H); 9-90 (s, 1H); 9-92 (bs, 2H); 10.09 (s, 1H).

Claims

1. Compounds as per general formula ( I)
where :
n = 0 or a whole number from 1 to 6
A = a single chemical bond or an alicyclic or aromatic or heterocyclic residue,
X1 = a chemical bond, the -NHCO- group or the -CONH- group
X2, X3 (either equal or different) = the -CONH- or -NHCO- group and where:
i) R1 and R2 (equal) = an oxiranomethyl or 1-aziridinomethyl or C2- C4 alkyl group, substituted in position 2, if required, by a hydroxy or C2-C4 alcoxy halogen or -OSO2R4 group, where:
R4 is C1-C4 alkyl or phenyl
or
ii) R1 = H, R2 as defined above
or
iii) R1 = H, R2 = -CO-(CH2)m-R3, where m is 0 or a whole number from 1 to 4 and R3 = halogen, oxiranyl or methyloxiranyl or azirinidyl, cyclopropyl or a C2-C6 alkenyl group substituted, if required, by halogens or a ketone or an α,β unsaturated alicylic lactone.
Considering that: if R1 and R2 are as defined under i) and ii) and X1 is a single chemical bond, A is a single chemical bond and n = 0;
if R1 and R2 are as defined under iii), X1 and A are single chemical bonds and n = 0;
if X1 is a single chemical bond or the -CONH- group and n = 0, X2 = X3 = -CONH- is impossible.
2. Compounds according to claim 1 wherein:
n is as defined above
A is a single cyclohexyl or p-phenylene or 1-methylpyrrole or thiophene or thiazole or imidazole or furan or isoxazole or oxazole or triazole or pyridine or pyrrole chemical bond
R1 and R2 (when R2 is not -CO-(CH2)m-R3) preferably stand for an ethyl or 2-chloroethyl or methanesulfonylethyl and when R2 = -CO- (CH2)m-R3, R3preferably stands for chlorine or bromine, or a 3- methyloxyranyl or ethenyl or l-chloroethenyl or 1-bromoethenyl group
where :
m = 0, 1, 2,
X1, X2, X3 are as defined above.
3. Compounds as per formula (I) according to claims 1 and 2 within the group:
3-[1-Methyl-4-[1-methyl-4-[1-methyl-4-[4-[N,N-bis(2-chloroethyl)- amino]benzenecarboxyamido]pyrrole-2-carboxyamido]pyrrole-2- aminocarbonyl]pyrrole-2-carboxyamido]propionamidino hydrochloride; 3-[1-Methyl-4-[1-methyl-4- [ 1-methyl-4-[4- [N,N-bis (2-chloroethyl) - amino]benzeneaminocarbonyl]pyrrole-2-carboxyamido]pyrrole-2- carboxyamido]pyrrole-2-carboxyamido]propionamidino hydrochloride; 3-[1-Methyl-4-[1-methyl-4-[1-methyl-4-[4-[N,N-bis(2-chloroethyl)- amino]benzeneaminocarbonyl]pyrrole-2-carboxyamido]pyrrole-2- aminocarbonyl]pyrrole-2-carboxyamido]propionamidino hydrochloride; 3-[1-Methyl-4-[1-methyl-4-[1-methyl-4-[4-[N,N-bis(2-chloroethyl)- amino]benzenecarboxyamido]pyrrole-2-aminocarbonyl]pyrrole-2- carboxyamido]pyrrole-2-carboxyamido]propionamidino hydrochloride ; 3-[1-Methyl-4-[1-methyl-4-[1-methyl-4-[4-[N , N-bis (2-chloroethyl) - amino]thiophene-2-carboxyamido]pyrrole-2-carboxyamido]pyrrole-2- aminocarbonyl]pyrrole-2-carboxyamido]propionamidino hydrochloride; 3-[1-Methyl-4-[1-methyl-4-[1-methyl-4-[1-methyl-4-[N,N-bis(2- chloroethyl)-amino]pyrrole-2-carboxyamido]pyrrole-2- carboxyamido]pyrrole-2-aminocarbonyl]pyrrole-2- carboxyamido]propionamidino hydrochloride;
3-[1-Methyl-4-[1-methyl-4-[1-methyl-4-[N , N-bis (2-chloroethyl) - amino ]pyrrole-2-carboxyamido]pyrrole-2-aminocarbonyl]pyrrole-2- carboxyamido]propionamidino hydrochloride;
3-[1-Methyl-4-[1-methyl-4-[ 1-methyl-4-[N,N-bis (2-chloroethyl) - amino]pyrrole-2-aminocarbonyl]pyrrole-2-carboxyamido]pyrrole-2- carboxyamido]propionamidino hydrochloride;
3-[1-Methyl-4-[1-methyl-4-[1-methyl-4-[N,N-bis(2-chloroethyl)- amino]pyrrole-2-aminocarbonyl]pyrrole-2-aminocarbonyl]pyrrole-2- carboxyamidojpropionamidino hydrochloride; 3-[1-Methyl-4-[1-methyl-4-[1-methyl-4-[6-[4-[N,N-bis(2-chloroethyl)- amino]phenyl]hexaneaminocarbonyl]pyrrole-2-carboxyamido]pyrrole-2- carboxyamido]pyrrole-2-carboxyamido]propionamidino hydrochloride; 3-[1-Methyl-4-[1-methyl-4-[1-methyl-4-(3-methyloxirano- carbonylamino)pyrrole-2-carboxyamido]pyrrole-2- aminocarbonyl ]pyrrole-2-carboxyamido]propionamidino hydrochloride ; 3-[1-Methyl-4-[1-methyl-4-[1-methyl-4- (cyclopropylcarbonylamino)pyrrole-2-carboxyamido]pyrrole-2- aminocarbonyl]pyrrole-2-carboxyamido]propionamidino hydrochloride; 3-[1-Methyl-4-[1-methyl-4-[1-methyl-4-[1-aziridino)
carbonylamino]pyrrole-2-carboxyamido]pyrrole-2- aminocarbonyl ]pyrrole-2-carboxyamido]propionamidino hydrochloride ; 3-[ 1-Methyl-4-[ 1-methyl-4-[ 1-methyl-4- ( α-chloroacrylamido ) pyrrole-2- carboxyamido]pyrrole-2-aminocarbonyl]pyrrole-2- carboxyamido]propionamidino hydrochloride;
3-[1-Methyl-4-[1-methyl-4-[1-methyl-4-[2[4-[N,N-bis(2-chloroethyl)- amino]phenyl]ethanaminocarbonyl]pyrrole-2-carboxyamido]pyrrole-2- carboxyamido]pyrrole-2-carboxyamido] propionamidino hydrochloride; 3-[ 1-Methyl-4- [ 1-methyl-4-[ 1-methyl-4-[4- [N , N-bis (2-chloroethyl ) - amino]benzylaminocarbonyl ]pyrrole-2-carboxyamido]pyrrole-2- carboxyamido ]pyrrole-2-carboxyamido]propionamidino hydrochloride ; 3-[ 1-Methyl-4- [ 1-methyl-4- [ 1-methyl-4- [3-[4-[N ,N-bis ( 2-chloroethyl ) - amino]-phenyl]propanamino-carbonyl]pyrrole-2-carboxyamido]pyrrole-2- carboxyamido]propionamidino hydrochloride;
3-[1-Methyl-4-[1-methyl-4-[1-methyl-4-[4-[4-[N,N-bis(2-chloroethyl)- amino]-phenyl]butanamido]pyrrole-2-aminocarbonyi]ρyrrole-2- carboxyamido]pyrrole-2-carboxyamido]propionamidino hydrochloride; N-deformyl-N-[4-[4-[N,N-bis(2-chloroethyl)amino]phenyl]
butanoyl]dystamicin hydrochloride.
4. Compounds as per general formula (II)
where X1, n, A, R1 and R2 are as defined in claims 1 and 2.
5. Compound as per formula (IV)
where X1, n. A, R1 and R2 are as defined in claims 1 and 2.
6. Compound as per formula (V)
where X3 is -CONH- or -NHCO-.
7. Compound as per formula (VI)
where X1, n. A, R1 and R2 are as defined in claims 1 and 2.
8. Compound as per formula (VII)
where n and A are as defined above, X1 stands for -CONH- or -NHCO-, R1 and R2 are as defined under i) and ii) of claim 1, and R5 is a protective group of a carboxylic acid.
9. Compound as per formula (XI)
where m and R3 are as defined in claims 1 and 2 and R5 is a protective group of a carboxylic acid .
10. Compound as per formula (XIV)
where X3 is -CONH- or -NHCO- and R6 is a protective group of a carboxylic acid.
11. Process for the preparation of compounds as per formula ( I )
where
n = 0 or a whole number from 1 to 6
A = a single chemical bond or an alicyclic or aromatic or heterocyclic residue.
X1 = a chemical bond, the -NHCO- group or the -CONH- group
X2 = the -CONH- group and X3 = the -CONH- or -NHCO- group
and where:
i) R1 and R2 (equal) = an oxiranomethyl or 1-aziridinomethyl or C2- C4 alkyl group, substituted in position 2, if required, by a hydroxy or C2-C4 alcoxy halogen or an -OSO2R4 group, where:
R4 is C1-C4 alkyl or phenyl
or
ii) R1 = H, R2 as defined above
or
iii) R1 = H, R2 = -CO-(CH2)m-R3, where m is 0 or a whole number from 1 to 4 and R3 = halogen, oxiranyl or methyloxiranyl or azirinidyl, cyclopropyl or a C2-C6 alkenyl group substituted, if required, by halogens or a ketone or an α,β unsaturated alicylic lactone.
Considering that:
if R1 and R2 are as defined under i) and ii) and X1 is a single chemical bond, A is a single chemical bond and n = 0;
if R1 and R2 are as defined under iii), X1 and A are single chemical bonds and n = 0;
if X1 is a single chemical bond or the -CONH- group and n = 0, X2 = X3 = -CONH- is impossible,
based on the reaction of compound as per formula (II)
where n. A, R1, R2 and X1 are as defined above, or a reactive derivative thereof, with compound as per formula (III)
where X3 is as defined above.
12. Process for the preparation of compounds as per formula (I)
where n, A, X1, X3, R1 and R2 are as defined in claim 11 and X2 is the -NHCO- based on the reaction of compound as per formula (IV)
where n, A, X1, R1 and R2 are as defined above, or a reactive precursor thereof, with compound as per formula (V)
where X3 is as defined in claim 11.
13. Process for the preparation of compound as per formula (II)
where n. A, R1 and R2 are as defined in claim 11 and X, is a chemical bond, the -NHCO- group or the -CONH- group
based on the hydrolysis of compound as per formula (VII)
where n, A, X1 , R1 and R2 are as defined above and R5 is a protective group of carboxylic acids.
14. Process for the preparation of compound as per formula (II)
where n, A, X1 are as defined in claim 11 and R1 and R2 are equal and stand for a C2-C4 alkyl group substituted in position 2 by a halogen or a -OSO2R4 group, where R4 = C1-C4 alkyl or phenyl, based on the reaction of compound as per formula (II), where n, A, and X1 are as defined above and R1 and R2 are equal and stand for a C2-C4 alkyl group substituted in position 2 by a hydroxy group, with a halogenating agent or a reactive derivative of an acid as per formula R4SO3H.
15. Process for the preparation of compound as per formula (IV)
where n. A, X1, R1 and R2 are as defined in claim 11, based on the rearrangement of azides as per formula (VI)
where n. A, X1, R1 and R2 are as defined above, at 50°C-100°C in the presence of an organic base.
16. Process for the preparation of compound as per formula (V)
where X3 = -NHCO- or -CONH- by reductive lysis of compound as per formula (XIV)
where X3 is as defined above and R6 is a protective group of carboxylic acids .
17. Process for the preparation of compound as per formula (VI)
where n, A, X1, R1 and R2 are as defined in claim 11
by causing compounds as per formula (II)
where n. A, X1, R1 and R2 are as defined above, to react with diphenylphosphorazide or sodium azide (NaN3).
18. Process for the preparation of compound as per formula (VII)
where n, A, R1 and R2 are as defined in claim 11 and X1 is the - CONH- group, based on the reaction of compound as per formula (VIII)
where n, A, R1 and R2 are as defined above, or a reactive derivative thereof, with compound as per formula (IX)
where R5 is a protective group of a carboxylic acid.
19. Process for the preparation of compound as per formula (VII)
where n. A, R1 and R2 are as defined in claim 11 and Xi is the -NHCO- group, by causing compound as per formula (XII)
where n. A, R1 and R2 are as defined above, to react with compound as per formula (XIII)
where R5 is a protective group of a carboxylic acid, or with a reactive derivative thereof.
20. Process for the preparation of compound as per formula (XI)
where R3 = halogen, oxiranyl or methyloxiranyl or azirinidyl, cyclopropyl or a C2-C6 alkenyl group substituted, if required, by halogens or a ketone or an α,β unsaturated alicylic lactone, m = 0 or a whole number between 1 and 4, and Re is a protective group of a carboxylic acid, by causing the corresponding acid and amine precursors to react under the traditional amidation conditions.
21. Process for the preparation of compound as per formula (XIV)
where X6 = -CONH- and R6 is a protective group of a carboxylic acid, based on the reaction of compound as per formula (XV)
where R6 is as defined above, or a reactive derivative thereof, with compound as per formula (XVI)
22. Process for the preparation of compound as per formula (XIV)
where X3 = -NHCO- and R6 is a protective group of a carboxylic acid, based on the reaction of compound as per formula (XVII)
where R6 is as defined above, or a reactive derivative thereof, with compound as per formula (XVIII).
23. Use of compounds according to claims 1 to 3 for the preparation of pharmaceutical compositions .
24 . Pharmaceutical compositions whose active ingredient is a compound according to claims 1 to 3 and a pharmaceutically acceptable vector or diluent.
25. Pharmaceutical compositions according to claim 24 as anticancer agents .
26. Pharmaceutical compositions according to claim 24 as antiviral agents .
27. Method for the treatment of tumoural diseases, envisaging the administration of pharmaceutical compositions whose active principle is a compound according to claims 1 to 3 in amounts ranging from 0.1 to 100 mg pro dose from 1 to 4 times/day and a pharmaceutically acceptable vector or diluent.
28. Method for the treatment of viral diseases, envisaging the administration of pharmaceutical compositions whose active principle is a compound according to claims 1 to 3 in amounts ranging from 0.1 to 100 mg pro dose from 1 to 4 times/day and a pharmaceutically acceptable vector or diluent.
EP93902141A 1992-01-10 1993-01-04 Retroreverse pyrrole-amidino oligopeptide anticancer agent analogues, preparation of same, and pharmaceutical compositions containing such analogues Withdrawn EP0623023A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI920021A IT1262921B (en) 1992-01-10 1992-01-10 ANALOGUE AGENTS ANALOGUES OF PYROL-AMIDINE OLIGOPEPTIDES BACK TO PREPARATION PROCESSES AND PHARMACEUTICAL PRODUCTS CONTAINING THEM
ITMI92021 1992-01-10
PCT/EP1993/000002 WO1993013739A2 (en) 1992-01-10 1993-01-04 Retroreverse pyrrole-amidino oligopeptide anticancer agent analogues, preparation of same, and pharmaceutical compositions containing such analogues

Publications (1)

Publication Number Publication Date
EP0623023A1 true EP0623023A1 (en) 1994-11-09

Family

ID=11361495

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93902141A Withdrawn EP0623023A1 (en) 1992-01-10 1993-01-04 Retroreverse pyrrole-amidino oligopeptide anticancer agent analogues, preparation of same, and pharmaceutical compositions containing such analogues

Country Status (4)

Country Link
EP (1) EP0623023A1 (en)
AU (1) AU3347893A (en)
IT (1) IT1262921B (en)
WO (1) WO1993013739A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1271456B (en) * 1993-03-01 1997-05-28 Menarini Farma Ind PYROL-AMIDINE COMPOUNDS, AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, PREPARATION PROCESSES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
IT1263089B (en) * 1993-04-26 1996-07-24 Menarini Farma Ind PYROL-AMIDINE COMPOUNDS, PREPARATION PROCESSES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US5821258A (en) * 1994-12-27 1998-10-13 Mitsui Chemicals, Inc. Phenylbenzimidazole derivatives
US5808087A (en) * 1995-11-29 1998-09-15 Mitsui Chemicals, Inc. Sulfonium salts of pyrrolylbenzimidazoles
GB9623522D0 (en) * 1996-11-11 1997-01-08 Pharmacia & Upjohn Spa Benzoheterocycle distamycin derivatives process for preparing them and their use as antitumour and antiviral agents
WO2001002359A1 (en) * 1999-07-01 2001-01-11 Ajinomoto Co., Inc. Heterocyclic compounds and medicinal use thereof
CN1427839A (en) 2000-03-16 2003-07-02 根索福特股份有限公司 Charged compounds comprising nucleic acid binding moiety and uses therefor
US7078536B2 (en) 2001-03-14 2006-07-18 Genesoft Pharmaceuticals, Inc. Charged compounds comprising a nucleic acid binding moiety and uses therefor
WO2002088119A1 (en) 2001-04-26 2002-11-07 Genesoft Pharmaceuticals, Inc Halogen-substituted thienyl compounds
AU2002312370A1 (en) 2001-06-13 2002-12-23 Roland W. Burli Antipathogenic benzamide compounds
DE60326735D1 (en) 2002-08-02 2009-04-30 Genesoft Pharmaceuticals Inc BIARYL COMPOUNDS WITH ANTI-INFECTIVE EFFECT
WO2004039318A2 (en) 2002-10-25 2004-05-13 Genesoft Pharmaceuticals, Inc. Anti-infective biaryl compounds
EP1587529A4 (en) 2002-12-10 2009-08-12 Oscient Pharmaceuticals Corp Antibacterial compounds having a (pyrrole carboxamide)-(benzamide)-(imidazole carboxamide) motif

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3420844A (en) * 1963-07-26 1969-01-07 Farmaceutici Italia Pyrrole-2-carboxamido-propionamidines
SE468642B (en) * 1985-07-16 1993-02-22 Erba Farmitalia POLY-4-AMINOPYRROL-2-CARBOXAMIDE DERIVATIVES AND PROCEDURES FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION
CN85103908A (en) * 1985-07-16 1986-11-05 法米塔利·卡洛·埃尔巴有限公司 Preparation 4 '-novel method of the red rhzomorph of Biao Duokesuo
GB8612218D0 (en) * 1986-05-20 1986-06-25 Erba Farmitalia Site specific alkylating agents
GB8906709D0 (en) * 1989-03-23 1989-05-10 Creighton Andrew M Acryloyl substituted pyrrole derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9313739A3 *

Also Published As

Publication number Publication date
ITMI920021A0 (en) 1992-01-10
WO1993013739A2 (en) 1993-07-22
IT1262921B (en) 1996-07-22
AU3347893A (en) 1993-08-03
WO1993013739A3 (en) 1993-11-25
ITMI920021A1 (en) 1993-07-10

Similar Documents

Publication Publication Date Title
EP2025676A1 (en) Novel indazole derivative having spiro ring structure in side chain
US5589490A (en) Benzoic acid substituted derivatives having cardiovascular activity
EP1641758B1 (en) Diphenylpyridine derivatives, preparation and therapeutic application thereof
EP0623023A1 (en) Retroreverse pyrrole-amidino oligopeptide anticancer agent analogues, preparation of same, and pharmaceutical compositions containing such analogues
HU211680A9 (en) Pyrazolopyridine compounds which have useful pharmaceutical utility
JP2001513767A (en) Reverse hydroxamate derivatives as metalloprotease inhibitors
EP4103564A1 (en) P2x3 modulators
US4431663A (en) Treatment of psychosis with meta-sulfonamido-benzamide derivatives
JPS63275561A (en) Substituted pyrroles
CA2240594C (en) 2,7-substituted octahydro-pyrrolo¬1,2-a|pyrazine derivatives
EP1819704B1 (en) Pyrrolopyridine-2-carboxylic acid amide derivative useful as inhibitor of glycogen phosphorylase
JP2003509417A (en) Tryptase inhibitor
NO885117L (en) SUBSTITUTED HYDROXYLAMINES.
WO2002098839A1 (en) Biphenylcarboxamides and process for preparation thereof
HU182670B (en) Process for preparing alpha-carbamoyl-pyrrole-propionitriles
WO1992009574A2 (en) Poly-aminopyrrolecarboxamido derivatives, processes for their preparation and pharmaceutical compositions containing them
EP3983387B1 (en) Sulfonylurea derivatives and uses thereof
US8980938B2 (en) CXCR2 inhibitors
WO2017008681A1 (en) Amide derivative, and preparation method and pharmaceutical use thereof
EP0663395B1 (en) 3-(phenylalkylaminoalkyloxy)-5-phenylpyrazole derivatives, process and intermediates for their preparation and their use as cardiac rhythm reduction agent
US4650868A (en) 7-deazapurine derivatives useful as antitumor agents
JPH01313460A (en) N-substituted n-amino-pyrrole
JP3376479B2 (en) Condensed pyrimidine derivatives, their production and use
JPH0417195B2 (en)
JPH04330060A (en) Di(nitroxyalkyl)amide of pyridine-2,4-and 2,5-dicarboxylic acid, and preparation and use thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940803

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE ES FR GB

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19970801